Abbonarsi

Clinical and molecular correlates of the Index of Severity for Eosinophilic Esophagitis - 05/08/24

Doi : 10.1016/j.jaci.2024.04.025 
Hiroki Sato, MD, PhD a, Evan S. Dellon, MD, MPH b, Seema S. Aceves, MD, PhD c, Nicoleta C. Arva, MD, PhD d, Mirna Chehade, MD, MPH e, Margaret H. Collins, MD a, Carla M. Davis, MD f, Gary W. Falk, MD, MS, MASGE g, Glenn T. Furuta, MD h, Nirmala P. Gonsalves, MD i, Sandeep K. Gupta, MD j, Ikuo Hirano, MD i, Girish Hiremath, MD, MPH k, David A. Katzka, MD l, Paneez Khoury, MD, MHSc m, John Leung, MD n, Paul Menard-Katcher, MD o, Robbie Pesek, MD p, Kathryn A. Peterson, MD q, Maria A. Pletneva, MD, PhD q, Jonathan M. Spergel, MD, PhD r, Joshua B. Wechsler, MD, MS s, Guang-Yu Yang, MD i, Marc E. Rothenberg, MD, PhD a, t, Tetsuo Shoda, MD, PhD a, t,
a Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio 
b University of North Carolina, Chapel Hill, NC 
c University of California San Diego School of Medicine, San Diego, Rady Children’s Hospital, San Diego, Calif 
d Nationwide Children’s Hospital, Columbus, Ohio 
e Icahn School of Medicine at Mount Sinai, New York, NY 
f Baylor College of Medicine, Texas Children’s Hospital, Houston, Tex 
g Penn Medicine, Philadelphia, Pa 
h Children’s Hospital Colorado, Aurora, Colo 
i Northwestern University Feinberg School of Medicine, Chicago, Ill 
j University of Alabama at Birmingham, Birmingham, Ala 
k Vanderbilt University Medical Center, Nashville, Tenn 
l Columbia University Irving Medical Center, New York, NY 
m National Institutes of Health, Bethesda, Md 
n Boston Specialists, Boston, Mass 
o University of Colorado Anschutz Medical Campus, Aurora, Colo 
p University of Arkansas for Medical Science, Little Rock, Ark 
q University of Utah Health, Salt Lake City, Utah 
r Children’s Hospital of Philadelphia, Philadelphia, Pa 
s Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Ill 
t University of Cincinnati College of Medicine, Cincinnati, Ohio 

Corresponding author: Tetsuo Shoda, MD, PhD, Division of Allergy and Immunology, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine: 3333 Burnet Ave, ML 7028, Cincinnati, OH 45229.Division of Allergy and ImmunologyCincinnati Children’s Hospital Medical CenterDepartment of PediatricsUniversity of Cincinnati College of Medicine: 3333 Burnet AveML 7028CincinnatiOH45229

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Abstract

Background

The Index of Severity for Eosinophilic Esophagitis (I-SEE) is a new expert-defined clinical tool that classifies disease severity of eosinophilic esophagitis (EoE).

Objective

We aimed to determine whether I-SEE is associated with patient characteristics, molecular features of EoE, or both.

Methods

We analyzed a prospective cohort of patients with EoE from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Associations between I-SEE and clinical and molecular features (assessed by an EoE diagnostic panel [EDP]) were assessed.

Results

In 318 patients with chronic EoE (209 adults, 109 children), median total I-SEE score was 7.0, with a higher symptoms and complications score in children than adults (4.0 vs 1.0; P < .001) and higher inflammatory and fibrostenotic features scores in adults than children (3.0 vs 1.0 and 3.0 vs 0, respectively; both P < .001). Total I-SEE score had a bimodal distribution with the inactive to moderate categories and severe category. EDP score correlated with total I-SEE score (r = −0.352, P < .001) and both inflammatory and fibrostenotic features scores (r = −0.665, P < .001; r = −0.446, P < .001, respectively), but not with symptoms and complications scores (r = 0.047, P = .408). Molecular severity increased from inactive to mild and moderate, but not severe, categories. Longitudinal changes of modified I-SEE scores and inflammatory and fibrostenotic features scores reflected histologic and molecular activity.

Conclusions

I-SEE score is associated with select clinical features across severity categories and with EoE molecular features for nonsevere categories, warranting further validation.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Eosinophilic esophagitis, diagnostic panel, eosinophil, complications, outcome

Abbreviations used : CEGIR, EDP, EGID, EoE, eos/hpf, FDR, IQR, I-SEE, m-I-SEE, OMEGA


Mappa


© 2024  American Academy of Allergy, Asthma & Immunology. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 154 - N° 2

P. 375 - Agosto 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Staphylococcus aureus–specific skin resident memory T cells protect against bacteria colonization but exacerbate atopic dermatitis–like flares in mice
  • Camille Braun, Cédric Badiou, Aurélie Guironnet-Paquet, Masashi Iwata, Vanina Lenief, Amandine Mosnier, Charlotte Beauclair, Emilie Renucci, Pauline Bouschon, Roxane Cuzin, Yoann Briend, Vijaykumar Patra, Sabine Patot, Tiffany C. Scharschmidt, Willem van Wamel, Nicole Lemmens, Saeko Nakajima, François Vandenesh, Jean-François Nicolas, Gérard Lina, Audrey Nosbaum, Marc Vocanson
| Articolo seguente Articolo seguente
  • A mutation in Themis contributes to anaphylaxis severity following oral peanut challenge in CC027 mice
  • Ellen L. Risemberg, Johanna M. Smeekens, Marta C. Cruz Cisneros, Brea K. Hampton, Pablo Hock, Colton L. Linnertz, Darla R. Miller, Kelly Orgel, Ginger D. Shaw, Fernando Pardo Manuel de Villena, A. Wesley Burks, William Valdar, Michael D. Kulis, Martin T. Ferris

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.